1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Deleterious drugs in COVID-19: a rapid systematic review and meta-analysis

Michael Holder^{1*}, Catherine Heeney^{1¶}, Stephen Malden^{1¶}, Uditha Perera^{1¶}, Aziz Sheikh¹

¹ Usher Institute, University of Edinburgh, Edinburgh, United Kingdom

* Corresponding author
E-mail: michael.holder2@nhs.scot (MH)

[¶]These authors contributed equally to this work.

1 Abstract

2 **Background:** Concerns have been expressed about a number of drugs that
3 potentially worsen outcomes in patients with COVID-19. We sought to identify all
4 potentially deleterious drug groups in COVID-19 and critically assess the
5 underpinning strength of evidence pertaining to the harmful effects of these drugs.

6 **Methods and findings:** We performed a rapid systematic review, searching
7 Medline, Embase and two COVID-19 portfolios (WHO COVID-19 database and
8 NIH iSearch COVID-19 portfolio) for papers and preprints related to primary
9 studies investigating drugs identified as potentially deleterious. Primary outcomes
10 were direct measures of susceptibility to infection, disease severity and mortality.
11 Study quality was assessed using the National Heart, Lung, and Blood Institute
12 quality assessment tools. Random-effects meta-analyses were used for data
13 synthesis with further subgroup analyses where possible for specific outcome, study
14 design, statistical adjustment and drug groups when two were combined.
15 Sensitivity analyses were performed by removing any studies at high risk of bias
16 and by publication status.

17 49 observational studies (15 peer-reviewed papers and 34 preprints) reported
18 primary outcomes for eight drug groups hypothesised to be deleterious. Meta-
19 analysis showed that acute inpatient corticosteroid use was associated with
20 increased mortality (OR 2.22, 95% CI 1.26-3.90), however this result appeared to
21 have been biased by confounding via indication. One subgroup analysis indicated
22 an association between immunosuppressant use and susceptibility to COVID-19
23 among case control and cross-sectional studies (OR 1.29, 95% CI 1.19-1.40) but this
24 was not found with cohort studies (OR 1.11, 95% CI 0.86-1.43). Studies which
25 adjusted for multiple confounders showed that people taking angiotensin-
26 converting-enzyme inhibitors (ACEIs) or angiotensin-II-receptor blockers (ARBs)
27 required a lower level of care (OR 0.85, 95% CI 0.74-0.98). Furthermore, studies

1 which combined these two drug groups in their analysis demonstrated an
2 association with a lower mortality (OR 0.68, 95% CI 0.55-0.85).

3 **Conclusions:** We found minimal high quality or consistent evidence that any drug
4 groups increase susceptibility, severity or mortality in COVID-19. Converse to initial
5 hypotheses, we found some evidence that regular use of ACEIs and ARBs prior to
6 infection may be effective in reducing the level of care required, such as requiring
7 intensive care, in patients with COVID-19.

8

1 Introduction

2 The ongoing Coronavirus 2019 (COVID-19) pandemic has already had a profound
3 global impact. As of 3rd March 2021, there had been over 114 million confirmed
4 cases and over 2.5 million deaths worldwide (1). SARS-CoV-2 is one of seven
5 coronaviruses known to infect humans (2). It is, together with severe acute
6 respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory
7 syndrome coronavirus (MERS-CoV), also one of three zoonotic human
8 betacoronaviruses to have emerged in the last 20 years (3). The genome sequence of
9 SARS-CoV-2 was found to be 79% similar to SARS-CoV (4); both viruses enter
10 human cells via angiotensin-converting enzyme 2 (ACE2), a factor linked to human-
11 to-human transmission (5). ACE2 received considerable attention following its
12 discovery as the entry for SARS-CoV, and has previously been purported to play a
13 protective role in disease, as opposed to the deleterious role of angiotensin-
14 converting enzyme (ACE) (6). Conversely, some hypothesized that drugs which
15 upregulate ACE2 may increase the risk of severe SARS-CoV-2 infection (7).

16 Approximately five percent of known COVID-19 cases require admission to an
17 intensive care unit (ICU) (8). Many of these patients develop acute respiratory
18 distress syndrome (ARDS) and require mechanical ventilation (MV) or other
19 respiratory support (9). Cytokine storms (a large release of pro-inflammatory
20 proteins) have been implicated in the development of ARDS, as well as multi-organ
21 failure, with a correlation between cytokine levels and mortality (10).

22 Since the beginning of the pandemic, both expert opinion and small-scale
23 observational studies have contributed to a number of drug groups being
24 postulated to alter the progression of the disease, whether positively or negatively.
25 At various times, conflicting advice regarding non-steroidal anti-inflammatory
26 drugs (NSAIDs) (11-13), corticosteroids (14, 15) and other immunosuppressants (16-
27 18), ACE Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) (19) have

1 been reported in the scientific literature and media, leading to considerable
 2 confusion for both patients and healthcare professionals.

3 Especially during the early stages of the pandemic, most of the advice stemmed
 4 from outcomes in other respiratory infections including severe acute respiratory
 5 syndrome (SARS) (20, 21) and Middle East respiratory syndrome (MERS) (14) or
 6 hypotheses based on the mechanism of viral entry into cells (19, 22, 23) and general
 7 effects on immunity (17, 18). In addition, many scientific papers have been
 8 published prior to peer review to speed up information sharing, which has led to
 9 questions surrounding the scientific validity of some of these findings (24).

10 We aimed to identify, critically appraise and synthesise the evidence on drugs
 11 which may be deleterious in COVID-19.

12 **Methods**

13 This study is reported as per PRISMA guidelines on the reporting of systematic
 14 reviews (25). In response to the exponential rate at which new research on this topic
 15 is being published, a rapid review methodology was adopted following the
 16 Cochrane rapid review protocol (26) with the aim of producing reliable results in a
 17 timely fashion.

18 **Search strategy**

19 As the availability of studies increased, our search strategy evolved iteratively to
 20 capture as much as possible of the available evidence base. This study consisted of a
 21 three-stage search strategy involving literature from four databases using the
 22 PECOS format (Population, Exposure, Comparison, Outcome, Study design):
 23 Embase, Medline, World Health Organization (WHO) COVID-19 Database (27) and
 24 National Institutes for Health (NIH) iSearch COVID-19 Portfolio (28). The searches
 25 were performed in April 2020 and included all papers between December 2019 and
 26 April 2020. We first searched the Medline and Embase databases simultaneously
 27 through Ovid, using a combination of Medical Subject Headings (MESH) and

1 keywords, to capture papers related to the drugs already identified as potentially
2 harmful in exploratory searches, as well as a string to identify new drugs.
3 (Appendix 1: search terms). The primary goal of this search was to amass a list of
4 drugs hypothesized as potentially harmful in COVID-19 in order to inform the
5 subsequent searches.

6 The second search was performed on the WHO COVID-19 Database (27), a database
7 aimed at compiling all the available publications on COVID-19. This search used
8 terms to capture evidence related to all drugs identified prior to the second search.

9 Due to the rapidity of emerging evidence, we felt we could not rely solely on peer-
10 reviewed publications as this would severely limit our findings and we decided to
11 include preprints a priori, which at the time were the primary source of information
12 available on COVID-19 epidemiology and pharmacovigilance (29). The third and
13 final search was, therefore, undertaken for preprints on the NIH iSearch COVID-19
14 Portfolio database, which included Research Square, medRxiv, chemRxiv, arXiv,
15 bioRxiv and Social Science Research Network. This search was screened for primary
16 data only.

17 **Screening**

18 As per the Cochrane rapid review guidelines (26), all abstracts were screened by the
19 first reviewer (MH). A second reviewer screened any excluded papers (SM and CH),
20 while a third reviewer helped to settle any disagreements (UP). All studies included
21 were then screened as a full text in the same manner, with all included full texts
22 being moved on to extraction. Finally, this process was repeated for reference lists
23 from all relevant systematic reviews identified from the searches.

24 The first two searches were initially screened with the aim of capturing a
25 comprehensive list of drugs hypothesized to be harmful and therefore included
26 opinion pieces. These searches were then screened a second time for papers with
27 primary data using a second set of inclusion and exclusion criteria (Appendix 2:

1 inclusion & exclusion criteria). The third search was screened only for primary data
2 using the second set of criteria.

3 **Data extraction**

4 Data extraction was performed using a tailored data extraction template designed to
5 capture relevant data pertaining to study design, setting, demographics and
6 findings (Appendix 5). Data from each study were extracted by the first reviewer
7 (MH) and checked independently by a second reviewer (UP).

8 **Quality assessment**

9 Quality assessment was performed using the National Heart, Lung, and Blood
10 Institute (NHLBI) checklists (30). We chose this tool for three reasons: it is a
11 validated and reliable tool; it contains checklists to assess a large range of
12 observational study designs;(13) and it is relatively simple and quick to administer
13 in comparison to other quality assessment tools, which aligned with the rationale
14 for adopting a rapid review methodology. Two of the four reviewers (MH and
15 SM/CH/UP) checked the quality of each study against the relevant checklist and
16 reached consensus through discussion when in disagreement.

17 No formal assessment of strength of evidence by outcome was undertaken;
18 however, we considered our findings in line with the key aspects of the grading of
19 recommendations assessment, development and evaluation (GRADE) (31).

20 **Outcome definitions**

21 Drug group analysis was split into three categories: susceptibility to infection;
22 severity of disease; and mortality. Susceptibility was defined as testing positive,
23 clinical diagnosis or hospitalisation (if compared with untested individuals) as these
24 all compared case numbers against those without the disease. Severity of disease
25 was split further where possible into either a diagnostic index or level of care.
26 Diagnostic index of severity was defined as any combination of factors used to

1 differentiate severe or critical disease from mild or moderate, or diagnostic criteria
2 for ARDS. Level of care was defined as hospitalisation (if compared with
3 community care of COVID-19 cases), ventilation (mechanical or non-invasive
4 ventilation), ICU care or mortality in combination with other outcomes including
5 remaining as an inpatient. Mortality was defined as any measure of mortality
6 outside of or within hospital, either within a set time frame or at any point during
7 data collection.

8 Although hospitalisation rates would normally imply more severe disease than
9 simply testing positive, in many countries testing was largely only available in
10 hospitals (32-34). If a study compared those admitted to hospital due to COVID-19
11 with untested individuals, this was considered analogous with testing positive for
12 the purpose of analysis. However, if the control group contained positive cases
13 tested in the community, then this was considered as requiring a higher level of
14 care.

15 Due to the common pathway affected by both ACEIs and ARBs, and the
16 recommendation against co-prescription (35), these drug groups were combined in
17 analyses. Henceforth, when combined, ACEIs and ARBs will be referred to as renin-
18 angiotensin-aldosterone blockers (RAASBs).

19 For the purposes of this review, we considered immunosuppressants as a class of
20 drugs used primarily to suppress the human immune system. Most included
21 studies investigated immunosuppressants in this manner, although some studies
22 analysed individual immunosuppressants. Where corticosteroids were grouped
23 together with other immunosuppressants, these studies were included here.

24 **Narrative synthesis**

25 For groups of outcomes for a particular drug group that had fewer than four effect
26 estimates with calculable and relevant odds ratios (ORs), these were synthesised

1 narratively. Study description tables were used to summarise study characteristics
2 and compare findings.

3 **Statistical analysis**

4 Any drug groups with a sufficient number of comparable studies were synthesised
5 using meta-analyses. Considering the implications of random-effects models on
6 statistical power (36), outcomes were deemed eligible for meta-analysis if more than
7 four studies were identified that investigated the same drug group. When sufficient
8 numbers of results were available, these were then run with sub-group analyses to
9 attempt to address any heterogeneity in the results and investigate which
10 confounding factors may have affected findings. The subgroup analyses included
11 study design, level of adjustment for confounders, acute doses or regular users, the
12 two subsets of disease severity defined above and whether ACEIs and ARBs were
13 analysed together or separately. Additionally, preprint studies that had not yet been
14 formally peer-reviewed were also removed during sensitivity analyses.

15 We included studies that either reported an OR, relative risk (RR) or the raw data
16 that allowed the calculation of OR in the meta-analyses. If available, we used an
17 adjusted OR, otherwise we used an unadjusted OR, either reported in the paper or
18 manually calculated. If the calculated OR exhibited a different result from the
19 conclusion reached by the paper, this was not included in the results.

20 If more than one outcome was reported, these were all included if they were in
21 different categories (i.e. severe disease and mortality). If multiple outcome subsets
22 were reported within the same categories, the outcome with the highest number of
23 patients in the exposed group, and therefore greatest weight, was used. The only
24 deviation from this was within the severity of disease category, where the
25 diagnostic index would take precedence to reduce any potential selection bias for
26 increased level of care.

1 We used MetaXL (Version 5.3; EpiGear International Pty Ltd) to run random-effects
 2 meta-analyses and create forest plots and funnel plots. Results were reported with a
 3 95% confidence interval (CI). We used Cochrane's Q and I^2 test to assess for
 4 heterogeneity. An $I^2 < 30\%$ was considered low heterogeneity, $\geq 30\%$ but $< 50\%$ was
 5 considered moderate and $\geq 50\%$ was considered high heterogeneity (37). Sensitivity
 6 analyses were performed on all models by removing each study to assess their risk
 7 of bias on the pooled effect estimates and heterogeneity. Publication bias was
 8 assessed for any meta-analyses that contained 10 or more studies by visually
 9 inspecting funnel plots for asymmetry.

10

1 Results

2 Eligible studies identified:

3 From the first two searches, we identified eight drug groups that were hypothesized
 4 to be deleterious in COVID-19 from 178 peer-reviewed publications comprising
 5 ACEIs, ARBs, corticosteroids, Immunosuppressants, mineralocorticoid receptor
 6 antagonists (MCRAs), NSAIDs, Statins and Thiazolidinediones (TZDs).

7 From the combined total of papers from all three searches, we identified 63 papers
 8 with primary data related to these drugs, with 49 measuring at least one primary
 9 outcome included in the study (Fig 1).

1

2 **Fig 1. PRISMA Flow Chart.** *PRISMA - Preferred Reporting Items for Systematic Reviews*
3 *and Meta-Analyses*

4 **Study characteristics:**

5 51% of the papers identified were from China (n=25). The remainder were either
6 from Europe (Denmark, France, Italy, Spain and United Kingdom (UK)), North
7 America (United States of America (USA)) or other parts of Asia (South Korea)

(Table 1). The majority of papers were cohort studies (n=29) and the remainder were either cross-sectional studies (n=9), case-control studies (n=8), case series (n=2) or a hybrid design (n=1). There were no experimental or quasi-experimental studies included in this review. Thirteen studies investigated more than one relevant drug, with one study (38) presenting data for all eight drug groups.

Table 1. Geographical Demographics of Included Studies and Peer-Review Status

Study Country	Number of studies (peer-reviewed)
China	25 (10)
USA	9 (2)
UK	4 (0)
Italy	3 (2)
Spain	3 (1)
France	2 (0)
South Korea	2 (0)
Denmark	1 (0)
Total	49 (15)

USA - United States of America, UK - United Kingdom.

Exposure status and outcome measures:

Most studies analysed outcomes for patients taking drugs regularly prior to contracting COVID-19. Studies that analysed ACEI, ARB, MCRA, statin and TZD usage measured outcomes only from those taking the drugs regularly, although one study compared outcomes of continued use of ACEIs and ARBs after admission with withdrawal of treatment (39). One study analysed acute treatment with the immunosuppressant tocilizumab (40), and one analysed acute treatment with the NSAID celecoxib (41). All the remaining studies, which looked at the use of drugs for treating COVID-19 focussed on corticosteroids. There was a mix of studies

1 assessing acute treatment doses of corticosteroids and those taking long-term
2 corticosteroids on severity of disease. All studies analysing susceptibility to
3 infection with corticosteroids assessed those taking long-term steroids and all
4 studies analysing mortality assessed those receiving acute doses.

5 **Quality assessment:**

6 The majority of the studies were assessed as being of fair quality (45%), followed by
7 good quality (35%); the remaining studies were assessed to be of high risk of bias
8 and rated as poor quality (20%). Generally, studies were downgraded due to limited
9 justifications of sample sizes used and insufficient controlling for potential
10 confounders.

11 **Sensitivity analysis by publication status:**

12 As a considerable portion of the included studies were published as preprints that
13 had not formally been peer-reviewed, we undertook sensitivity analysis on any of
14 these studies eligible for meta-analysis to determine their influence on the overall
15 effect estimates when included in random-effects models. None of the included
16 preprints were found to significantly influence any of these results, described
17 below, and they were therefore included in the analyses. Results of the sensitivity
18 analyses can be viewed in Appendix 7.

19 **MCRAAs, NSAIDs, Statins and TZDs**

20 For four of the drug groups (MCRAAs, NSAIDs, statins and TZDs), meta-analysis
21 revealed no evidence of protection or harm for any of the groups of outcomes. None
22 of these drug groups had any studies analysing mortality, and only NSAIDs had
23 enough studies analysing severity of disease to perform a meta-analysis (Appendix
24 6 – Fig 14). No pooled effect estimates showed any statistically significant evidence
25 of harm in patients with COVID-19 (Table 2) (Appendix 6 – Figs 15-17).

26

1 Table 2. Summary of results for MCRAs, NSAIDs, statins and TZDs

Drug	Studies (n)	Susceptibility (n)	Pooled effect	Severity (n)	Pooled effect	Mortality (n)	Pooled effect
NSAIDs	9	5	OR 1.04 (95% CI 0.91-1.18)	6	OR 0.90 (95% CI 0.66-1.22)	-	-
Statins	5	4	OR 1.04 (95% CI 0.87-1.25)	2	-	-	-
TZDs	4	4	OR 1.04 (95% CI 0.61-1.79)	1	-	-	-
MCRAs	2	2	-	-	-	-	-

2 NSAIDs – non-steroidal anti-inflammatory drugs, TZDs – thiazolidinediones, MCRAs –
3 mineralocorticoid receptor antagonists. Effects of drug groups on susceptibility

4 Results of studies looking into the effect of drug groups on the susceptibility to
5 COVID-19 infection are summarised in Appendix 3 - **Table 3**.

6 RAASB

7 Ten studies were used in the meta-analysis of susceptibility to COVID-19 with
8 RAASBs (33, 38, 42-49). Seven stratified their results into those taking ACEIs and
9 those taking ARBs, and three combined the two drug groups (**Fig 2**).

10 The total pooled effect estimate from all the studies showed no evidence that
11 RAASBs affect the risk of contracting COVID-19 (OR 0.94; 95% CI 0.82-1.07). Visual
12 inspection of the funnel plot showed no evidence of publication bias (Appendix 4 -
13 Fig 12). When split into subgroups for drug group, study design and statistical
14 adjustment, this result was unchanged (Appendix 6 – Figs 18-20).

Fig 2. Forest plot for susceptibility to COVID-19 for those taking regular RAASBs.

ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio, CI – confidence interval.

Corticosteroids

Four studies investigated the effects of corticosteroids on susceptibility to COVID-19 (38, 44, 48, 49). One study, rated as good quality, measured only those taking inhaled corticosteroids (38), therefore meta-analysis was not conducted. This study was also the only one to report an increased risk of contracting COVID-19 amongst patients taking corticosteroids, with the remaining three studies reporting null effects (Appendix 3 – Table 3).

Immunosuppressants

Five studies (32, 38, 44, 46, 48) analysing the effect of immunosuppressants on susceptibility to COVID-19 were included in the meta-analysis (Fig 3).

The initial analysis showed no statistically significant evidence of harm or benefit (OR 1.11; 95% CI 0.86 – 1.43). Sensitivity analysis showed removal of Rentsch, CT et al resulted in a statistically significant movement of the pooled effect in the direction of harm (OR 1.29; 95% CI 1.19 - 1.40; I^2 0%), but was 96.9% weighted towards the result from Mancia, G et al. When analysed as subgroups based on study design, we

1 found the same result for case-control and cross-sectional studies (OR 1.29; 95% CI
2 1.19 – 1.40) (Fig 3).
3 The only study looking at susceptibility that was not included in the meta-analysis
4 (50) looked at individual immunosuppressive drugs compared against each other,
5 finding janus kinase inhibitor usage was more prevalent among rheumatology
6 patients with COVID-19, whereas no evidence of a protective or harmful effect of
7 methotrexate was observed.

8
9 **Fig 3. Forest plot for effect of immunosuppressants on susceptibility to COVID-19,**
10 **stratified by study design. OR – odds ratio, CI – confidence interval.**

Effects of drug groups on severity

Results of studies looking into the effect of drug groups on the severity of COVID-19 infection are summarised in Appendix 3 – Table 4.

RAASB

Among the total pool of studies, there was no evidence of benefit or harm with RAASBs (OR 0.93; 95% CI 0.77 – 1.12) (Fig 4). No individual studies affected either the pooled effect estimate or the heterogeneity. Visual inspection of the funnel plot showed no evidence of publication bias (Appendix 4 - Fig 13).

Fig 4. Forest plot of effect of RAASBs on severity of COVID-19. ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio, CI – confidence interval.

Subgroup analyses consisting of three subgroups: either no or insufficient adjustment and compared against a general population; compared against hypertensive controls; and what we considered sufficiently adjusted results

(adjustment for at least age, sex and one or more co-morbidities) was performed. This showed statistically significant evidence of a protective effect from ACEIs and ARBs for adjusted results (OR 0.86; 95% CI 0.77 – 0.96) (Fig 5). Sensitivity analysis showed that the removal of the result from Bean, DM et al (51) removed the statistically significant pooled effect estimate (OR 0.90; 95% CI 0.80 – 1.02).

Fig 5. Forest plot of effect of RAASBs on severity of COVID-19 stratified by adjustment. ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio, CI – confidence interval.

1 Creating diagnostic severity index or higher level of care subgroups showed
2 statistically non-significant and heterogeneous results (OR 0.84; 95% CI 0.56 – 1.27; I^2
3 45% and OR 0.94; 95% CI 0.77 - 1.15; I^2 62%, respectively). When these two groups
4 were analysed separately and subgroup analysis was run for level of adjustment,
5 this showed a statistically non-significant result for adjusted studies using the
6 severity index (OR 0.77; 95% CI 0.39 – 1.49). However, further statistically significant
7 evidence of benefit for RAASBs among adjusted studies in regard to the highest
8 level of care needed was observed (OR 0.85; 95% CI 0.74 – 0.98) (Fig 6). Again,
9 removal of the result from Bean, DM et al (51) made the result statistically non-
10 significant. This stratification also showed statistically significant evidence of harm
11 from unadjusted studies (OR 1.63; 95% CI 1.16 - 2.31).

12
13 **Fig 6 Forest plot of effect of RAASBs on the highest level of care needed, stratified by**
14 **level of adjustment. ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-**
15 **receptor blocker, OR – odds ratio, CI – confidence interval.**

Corticosteroids

Eight studies with verifiable data assessed the risk of corticosteroids increasing the risk of developing severe disease (49, 52-58). The majority were cohort studies, which varied by study quality and other methodological factors (Appendix 3 – Table 4).

Four cohort studies measured outcomes from acute treatment doses of corticosteroids, reaching different conclusions; however, one study did not have a calculable OR and so a meta-analysis was not possible.

The four studies which used long-term steroids as their exposure were analysed together in a meta-analysis. One study ran different analyses for oral and inhaled steroids. As these can be co-prescribed, this analysis was run twice with each model including either the inhaled or oral corticosteroid measurement. Neither model showed statistically significant evidence of harm or benefit for severity of COVID-19 for those taking long-term steroids (inhaled corticosteroids = OR 1.40; 95% CI 0.81 – 2.39; I^2 36%; oral corticosteroids = OR 1.36; 95% CI 0.76 – 2.45; I^2 44% (Fig 7)).

16

17

Fig 7. Forest plot of effect of regular corticosteroids on severity of COVID-19. OR – odds ratio, CI – confidence interval.

Immunosuppressants

Meta-analysis was conducted on four studies (46, 54, 56, 59) of severity of COVID-19 in those taking immunosuppressants. All four were cohort studies and all scored

1 poorly on aspects of controlling for confounding during quality assessment
 2 (Appendix 3 – Table 4).
 3 The pooled effect estimate showed no statistically significant evidence of benefit or
 4 harm (OR 0.68; 0.27 – 1.71) (Fig 8).

5
 6 **Fig 8. Forest plot for effect of immunosuppressants on severity of COVID-19. OR –**
 7 *odds ratio, CI – confidence interval, ARDS – acute respiratory distress syndrome.*

8 The studies not included in this meta-analysis reached opposing conclusions, but in
 9 very different scenarios. The only study to look at acute usage of tocilizumab (40)
 10 was a case control study, finding evidence of benefit in terms of requiring
 11 ventilation (OR 0.42; 95% CI 0.2 – 0.89) or ICU care (OR 0.17; 95% CI 0.06-0.48). An
 12 additional case control study (60) , found that those on immunosuppressants had
 13 more severe COVID-19 when compared with their family members who tested
 14 positive for SARS-CoV-2, but no OR was available nor calculable.

15 **Effects of drug groups on mortality**

16 Results of studies looking into the effect of drug groups on mortality in COVID-19
 17 infection are summarised in Appendix 3 – Table 5.

18 **RAASB**

19 Eight studies investigated death rates among those taking RAASBs (61-68) with six
 20 grouping them together and two analysing ACEIs and ARBs separately (Appendix
 21 3 – Table 5).

22 None of these studies adjusted their results, although three used a hypertensive
 23 control group. When subgroup analysis was undertaken to reflect these, it showed

- 1 no evidence of harm or benefit against hypertensive controls (OR 0.91; 95% CI 0.62 –
- 2 1.32), the general population (OR 1.11; 95% CI 0.67 – 1.85) or for the pooled effect
- 3 overall (OR 0.97; 95% CI 0.74 – 1.29) (Fig 9).

4
5 **Fig 9. Forest plot of effect of RAASBs on mortality, stratified by control group.** ACEI –
6 angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds
7 ratio, CI – confidence interval.

- 8 Subgroup analysis of studies which combined RAASBs showed a pooled effect
- 9 estimate exhibiting statistically significant evidence of benefit (OR 0.68; 95% CI 0.55
- 10 – 0.85) with low heterogeneity (I² 5%) (Fig 10). During sensitivity analysis, the result
- 11 became statistically non-significant if the results from either Ip, A et al or Sánchez-
- 12 Álvarez, JE et al were removed. These two studies were also the only two in this
- 13 analysis that were rated as poor during the quality assessment.

Fig 10. Forest plot for effect of RAASBs on mortality in COVID-19, stratified by drug group. ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio, CI – confidence interval.

Two studies were not included in the meta-analysis, each reporting conflicting results with regards to mortality (69, 70) (Appendix 3 – Table 5).

Corticosteroids

Seven (62, 67, 71-75) of the 10 studies assessing mortality in those given corticosteroids were included in the meta-analysis. All of these analysed acute doses used to treat COVID-19 admissions in hospital (Appendix 3 – Table 5). Two studies (55, 76) reported no evidence of harm or benefit but it was not possible to extract summary data for pooled analysis. The remaining study (54) compared hazard ratios (HRs) for high and low dose corticosteroids, finding a low-dose had no evidence of either harm or benefit (HR 1.26; 95% CI 0.61 – 2.58), but a high-dose showed evidence of increased mortality (HR 3.5; 95% CI 1.79 – 6.86).

1 Meta-analysis of the remaining studies showed evidence of harm (OR 2.22; 95% 1.26
2 – 3.90) (Fig 11). The authors of three of the studies highlighted confounding by
3 indication as a likely factor considerably affecting their results, and when these
4 studies were removed, the pooled effect estimate showed there was no clear
5 evidence of an effect (OR 1.48; 95% CI 0.73 – 3.00; I^2 67%).

6
7 **Fig 11. Forest plot of effect of corticosteroids on mortality.** OR – odds ratio, CI –
8 confidence interval.

9 *Immunosuppressants*

10 Two studies analysed mortality rates in those taking immunosuppressants. (40, 59).
11 Neither found statistically significant evidence of increased or decreased mortality
12 (OR 0.88; 95% CI 0.17 – 4.46 and OR 0.90; 95% CI 0.24 – 3.42, respectively)
13 (Appendix 3 – Table 5).

14
15
16

1 Discussion

2 Statement of principal findings

3 This rapid systematic review and meta-analysis attempted to identify and assess
 4 any potentially deleterious drug groups in covid-19 susceptibility and prognosis. In
 5 terms of susceptibility to infection, we found no pooled effect estimates and one
 6 subgroup analysis with statistically significant evidence of increased susceptibility
 7 (Fig 3), which would be in keeping with many other infections and a known risk of
 8 immunosuppressant use (77). Hence, we found no evidence to suggest that those
 9 without COVID-19 should stop taking their medication to reduce their risk of
 10 contracting the disease. Stopping immunosuppressants may also result in a flare-up
 11 of a person's underlying condition, which can result in increased risk of infection
 12 (78). Furthermore, the withdrawal of any necessary medications could cause harm
 13 from the disease the drug was being used to treat, as well as from a potentially
 14 severe form of COVID-19 for people with hypertension and diabetes who are
 15 already at increased risk (79, 80).

16 We found no evidence that long-term use of any of these drugs increases the
 17 severity of disease, nor the mortality rates. One subgroup analysis of RAASBs
 18 showed a statistically significant relationship between RAASB usage and requiring
 19 a higher level of hospital care (Fig 6). However, this was found in an unadjusted
 20 subgroup where the adjusted subgroup showed evidence of protection, highlighting
 21 the effect of known confounders, such as age and cardiovascular disease (81), on the
 22 results from these observational studies. This evidence of protection against more
 23 severe disease was also shown by the pooled effect of all adjusted studies analysing
 24 severity (Fig 5).

25 Strengths and limitations

26 This rapid systematic review and meta-analysis has synthesised the best available
 27 evidence from the first few months of the pandemic for each of these drugs when

1 taken by those with or at risk of COVID-19. This study has, within the limitations
2 imposed by time and the unparalleled research publication rate, aimed to compile a
3 comprehensive list of drugs that were hypothesized to be deleterious in peer-
4 reviewed papers at the time of the searches.

5 This review however has several limitations. The rapidity with which research is
6 being produced and published affected our study in a number of ways. Firstly, we
7 acknowledge that while a rapid review is justifiable on the grounds of swifter
8 completion, it is less robust than a systematic review. Secondly, the studies included
9 in this review were also completed within a short space of time in order to attempt
10 to learn from clinical practice as quickly as possible. As a result of this, many papers
11 that would be relevant to this review, including papers with stronger evidence and
12 more robust methodology than some of those included may now be available.
13 Finally, the research landscape is changing so quickly that the studies included in
14 this review were all published prior to conducting the last search. This will bias our
15 results towards the studies that were produced more quickly and in countries that
16 experienced larger COVID-19 case numbers earlier on in this outbreak. These
17 countries may have large differences in their demographics as well as clinical
18 protocols for both pre-existing co-morbidities and COVID-19, which could impact
19 the generalisability of our findings.

20 Another factor heightening the risk of bias, errors and methodological inadequacies,
21 is the lack of peer-reviewed articles and the use of preprints in this review. We
22 conducted a sensitivity analysis in January 2021 to analyse whether the removal of
23 papers that had not made it through the peer-review process at this point affected
24 the results, but there were no significant changes to the pooled outcomes (Appendix
25 7). Nevertheless, we must emphasise that because we have included preprints, the
26 results from this review are only to highlight potential outcomes to evaluate with
27 further studies and should not be used to alter clinical practice.

1 As all of the evidence in this review is from observational studies, this introduces a
 2 risk of bias from confounding factors, despite many studies attempting to
 3 statistically adjust for these. Any confounders not adjusted for or as yet unknown
 4 will have affected our results. One example of this is the discovery that people with
 5 a Black, Asian or minority ethnic background are at an increased risk of severe
 6 COVID-19 (82), something that was not apparent at the beginning of the outbreak
 7 and was therefore only adjusted for in five of the studies included in the review.
 8 Other biases evident in the studies included confounding by indication, most
 9 evident among the studies looking at acute treatment of COVID-19 with
 10 corticosteroids, and misclassification bias in studies where it was possible the
 11 control group had been buying the drug of interest over-the-counter or had stopped
 12 taking it immediately prior to admission to hospital. This happened with NSAIDs
 13 for example.

14 Using aspects of the GRADE assessment, the quality of evidence presented in this
 15 review could be classified as low, primarily due to inconsistency, indirectness,
 16 imprecision and risk of bias across each outcome (31).

17 **Interpretation in light of the wider literature**

18 One of the reasons RAASBs, MCRAs, NSAIDs, Statins and TZDs were hypothesized
 19 to be harmful is their potentially upregulating effect on ACE2, this being the entry
 20 point into cells for SARS-CoV-2. Although there are studies which have shown that
 21 all of these drugs may upregulate ACE2, particularly RAASBs, the evidence is
 22 largely from animal studies, and some of it is contradictory (83). We found no
 23 evidence to suggest any of these drugs worsen outcomes or increase the
 24 susceptibility to contracting COVID-19 and some evidence to suggest RAASBs
 25 could be protective. Whilst it is unclear if this is related to their effect on ACE2, it
 26 appears that the protective nature of ACE2 may in fact provide a target for treating
 27 COVID-19 (84). Studies have also shown similar protective effects of ACEIs (85),
 28 ARBs and statins (86) in non-COVID pneumonias.

1 Another prominent reason for drugs to be hypothesized to worsen outcomes was
 2 immunosuppression. Advice emerged early on advising against using steroids in
 3 COVID-19 (14), but this was at odds with the experiences of front-line clinical
 4 workers in China who were using it in a large number of cases (87). Guidance
 5 surrounding long-term immunosuppressants in those with COVID-19 was also
 6 issued (88), however at the same time it appeared that dampening the immune
 7 response may have a role in treating acute infections (89). With the discovery that
 8 interleukin 6 (IL-6) was elevated in patients with severe COVID-19 (90), IL-6
 9 antagonists such as tocilizumab started to be used therapeutically (91). We only
 10 found one study which analysed the outcomes of those treated with tocilizumab
 11 and this found a reduction of ICU admissions and need for ventilation when
 12 patients were given tocilizumab (40). This was an observational study where the
 13 patients were “highly selected” so, although the results were adjusted for
 14 confounders, there remains a risk of bias.

15 The majority of studies included in this review measured outcomes in patients
 16 taking drugs regularly. We only found one study (39) comparing patients who had
 17 the drug withheld during the acute infection with those that continued to take them.
 18 This study found no effect on disease severity or mortality but found statistically
 19 significant reduction in viral clearance and length of stay in those in whom RAASBs
 20 were withheld during their hospital stay. This area requires more research, as any
 21 conclusions we draw from this review can only be applied to those who take these
 22 medications prior to the onset of COVID-19. In order to guide clinical practice,
 23 studies comparing initiated, continued and withheld medications, ideally
 24 randomised controlled trials (RCTs), are paramount (92).

25 With most drug groups included in this review, dosage and timing was not usually
 26 measured or analysed. One study of corticosteroids compared the effect of the
 27 cumulative dose of steroids and the authors concluded that mortality with high-
 28 dose steroids was higher than with low-dose steroids (54). Another study which
 29 found favourable outcomes for corticosteroids as a treatment for COVID-19

1 hypothesized that the timing was also important, opting for low dose steroids early
 2 on in the disease progression (93). These hypotheses were similarly at risk of
 3 confounding by indication, with those going on to develop ARDS more likely to get
 4 higher dose steroids at a later point in time.

5 **Implications for policy, practice and research**

6 This review contains exclusively observational studies, many of which have not
 7 been peer-reviewed, and so we do not recommend any changes to normal
 8 prescribing practice. However, we have found no evidence to suggest medications
 9 should be stopped solely due to contracting COVID-19. This goes along with
 10 guidelines published for many of these drug groups (94-96) and the findings of
 11 other rapid reviews (28, 97).

12 For those taking the drugs highlighted in this review, the binary decision between
 13 stopping and continuing their medications, coupled with the contrasting advice
 14 from experts, the media and governments, helped fuel the false dichotomy that
 15 drug groups were either harmful or not. Due to the large number of factors that can
 16 affect outcomes in COVID-19, the harm or benefit derived from starting, stopping or
 17 continuing drugs will affect individuals differently, with co-morbidities,
 18 demographics, other medications and individual response to the virus playing a
 19 role in the progression of the disease. However, this review raises the prospect that
 20 drug groups that have been hypothesized to be deleterious in COVID-19, may have
 21 the potential to be beneficial in certain circumstances. This is evidenced further by a
 22 number of clinical trials, either planned, in progress or completed, involving drugs
 23 or drug groups identified during this review (98-103).

24 Furthermore, where trials are unfeasible, as in the case where the aim is to examine
 25 the effects of long-term drug use on COVID-19, good quality, large-scale
 26 observational studies will be necessary to form the best possible evidence. RCTs will
 27 understandably be focussed on finding drugs used to treat COVID-19, the results of

1 which are beginning to be published (98). However, trials looking at treatments
2 with drugs included in this review may help inform their use in other contexts.

3 **Conclusions**

4 We have highlighted the gaps in the research, such as the lack of RCTs and
5 mortality data for NSAIDs, immunosuppressants and long-term steroid use. We
6 have proposed that there should be some focus in future research on these gaps as
7 well as the use of ACE2, or drugs which upregulate it, as a potential target for
8 treating COVID-19.

9 This study found a total of eight drug groups hypothesized to be deleterious in
10 COVID-19. The available data from the first few months of the current pandemic
11 suggest that there is little to no evidence these drug groups increase susceptibility,
12 severity or mortality in COVID-19 and we found some evidence that ACEIs and
13 ARBs may be protective in preventing a more severe disease.

14 **References**

- 15 1. Johns Hopkins University. Coronavirus Resource Centre 2020 [cited 2020 3
16 April]. Available from: <https://coronavirus.jhu.edu/>.
- 17 2. Centers for Disease Control and Prevention. Human Coronavirus Types 2020
18 [cited 2020 Jul 11]. Available from: <https://www.cdc.gov/coronavirus/types.html>.
- 19 3. European Centre For Disease Prevention and Control. Coronaviruses 2020
20 [cited 2020 Jul 11]. Available from: [https://www.ecdc.europa.eu/en/covid-19/latest-](https://www.ecdc.europa.eu/en/covid-19/latest-evidence/coronaviruses)
21 [evidence/coronaviruses](https://www.ecdc.europa.eu/en/covid-19/latest-evidence/coronaviruses).
- 22 4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
23 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
24 binding. *Lancet*. 2020;395(10224):565-74.
- 25 5. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus
26 associated with human respiratory disease in China. *Nature*. 2020;579(7798):265-9.
- 27 6. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD.
28 Angiotensin converting enzyme-2 is protective but downregulated in human and
29 experimental lung fibrosis. *Am J Physiol Lung Cell Mol Physiol*. 2008;295(1):L178-
30 85.
- 31 7. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes
32 mellitus at increased risk for COVID-19 infection? *The Lancet Respiratory Medicine*.
33 2020;8(4):e21.

- 1 8. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
2 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
3 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA.
4 2020;323(13):1239-42.
- 5 9. Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With
6 COVID-19. JAMA. 2020;323(15):1499-500.
- 7 10. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm'
8 in COVID-19. J Infect. 2020;80(6):607-13.
- 9 11. Medicines and Healthcare Regulatory Agency. Ibuprofen use and
10 Coronavirus (COVID-19) 2020 [cited 2020 2 April]. Available from:
11 <https://www.gov.uk/government/news/ibuprofen-use-and-covid19coronavirus>.
- 12 12. Day M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ.
13 2020;368:m1168.
- 14 13. Reality Check Team, BBC Monitoring. Coronavirus and ibuprofen: Separating
15 fact from fiction: BBC News,; 2020 [cited 2020 Jul 14]. Available from:
16 <https://www.bbc.co.uk/news/51929628>.
- 17 14. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
18 corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395(10223):473-
19 5.
- 20 15. Hartmann-Boyce J, Hobbs R. Inhaled Steroids in Asthma during the COVID-
21 19 Outbreak: CEBM; 2020 [cited 2020 Jul 14]. Available from:
22 [https://www.cebm.net/covid-19/inhaled-steroids-in-asthma-during-the-covid-19-](https://www.cebm.net/covid-19/inhaled-steroids-in-asthma-during-the-covid-19-outbreak/)
23 [outbreak/](https://www.cebm.net/covid-19/inhaled-steroids-in-asthma-during-the-covid-19-outbreak/).
- 24 16. Kovarik JM, Burtin P. Immunosuppressants in advanced clinical development
25 for organ transplantation and selected autoimmune diseases. Expert Opin Emerg
26 Drugs. 2003;8(1):47-62.
- 27 17. Manez R, Kusne S, Linden P, Gonzalez-Pinto I, Bonet H, Kramer D, et al.
28 Temporary withdrawal of immunosuppression for life-threatening infections after
29 liver transplantation. Transplantation. 1994;57(1):149-51.
- 30 18. Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID-19 and
31 psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.
32 Dermatologic Therapy. 2020.
- 33 19. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et
34 al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor
35 blockers on cardiac angiotensin-converting enzyme 2. Circulation.
36 2005;111(20):2605-10.
- 37 20. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say
38 doctors and scientists. BMJ. 2020;368:m1086.
- 39 21. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ.
40 2020;368:m1185.
- 41 22. Aronson J, Ferner RE. Angiotensin converting enzyme (ACE) inhibitors and
42 angiotensin receptor blockers in COVID-19: CEBM; 2020 [cited 2020 Jul 14].
43 Available from: [https://www.cebm.net/covid-19/angiotensin-converting-enzyme-](https://www.cebm.net/covid-19/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/)
44 [ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/](https://www.cebm.net/covid-19/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/).

23. Cure E, Cumhur Cure M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. *Diabetes Metab Syndr*. 2020;14(4):349-50.
24. Sharm MS, S; Kelland, K. Coronavirus and the risks of 'speed science': World Economic Forum; 2020 [cited 2020 2 April]. Available from: <https://www.weforum.org/agenda/2020/03/speed-science-coronavirus-covid19-research-academic>.
25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
26. Garritty C, Gartlehner G, Kamel C, King V, Nussbaumer-Streit B, Stevens A, et al. Cochrane Rapid Reviews. Interim Guidance from the Cochrane Rapid Reviews Methods Group. 2020.
27. World Health Organization. Global research on coronavirus disease (COVID-19) 2020 [cited 2020 2 April]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov>.
28. World Health Organization. COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers 2020 [cited 2020 Jul 29]. Available from: <https://www.who.int/publications/i/item/covid-19-and-the-use-of-angiotensin-converting-enzyme-inhibitors-and-receptor-blockers>.
29. Gianola S, Jesus TS, Barger S, Castellini G. Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic. *PLOS ONE*. 2020;15(10):e0240123.
30. National Heart Lung and Blood Institute. Study Quality Assessment Tools 2014 [cited 2020 June]. Available from: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>.
31. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924-6.
32. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. *J Am Acad Dermatol*. 2020;83(1):285-7.
33. Khawaja AP, Warwick AN, Hysi PG, Kastner A, Dick A, Khaw PT, et al. Associations with covid-19 hospitalisation amongst 406,793 adults: the UK Biobank prospective cohort study. *medRxiv*. 2020. [preprint]
34. Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, et al. Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zhejiang Province, China. *medRxiv*. 2020. [preprint]
35. National Institute for Health and Care Excellence. Renin-angiotensin system drugs: dual therapy 2015 [cited 2020 Jul 20]. Available from: <https://www.nice.org.uk/advice/ktt2/chapter/evidence-context>.

- 1 36. Jackson D, Turner R. Power analysis for random-effects meta-analysis. *Res*
2 *Synth Methods*. 2017;8(3):290-302.
- 3 37. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Chapter
4 10: Analysing data and undertaking meta-analyses. *Cochrane handbook for*
5 *systematic reviews of interventions*. Version 6 ed: John Wiley & Sons; 2019.
- 6 38. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-
7 Aldosterone System Blockers and the Risk of Covid-19. *N Engl J Med*.
8 2020;382(25):2431-40.
- 9 39. Huang L, Chen Z, Ni L, Chen L, Zhou C, Gao C, et al. Impact of Angiotensin-
10 converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Inflammatory
11 Responses and Viral Clearance in COVID-19 Patients: A Multicenter Retrospective
12 Cohort Study. *Research Square*. 2020. [preprint]
- 13 40. Roumier M, Paule R, Groh M, Vallee A, Ackermann F. Interleukin-6 blockade
14 for severe COVID-19. *medRxiv*. 2020. [preprint]
- 15 41. Hong W, Chen Y, You K, Tan S, Wu F, Tao J, et al. Celebrex adjuvant therapy
16 on COVID-19: An experimental study. *medRxiv*. 2020. [preprint]
- 17 42. Caraballo C, McCullough M, Fuery M, Chouairi F, Keating C, Ravindra N, et
18 al. COVID-19 Infections and Outcomes in a Live Registry of Heart Failure Patients
19 Across an Integrated Health Care System. *medRxiv*. 2020. [preprint]
- 20 43. Dooley H, Lee K, Freidin M, Hemani G, Roberts A, Lavigne du Cadet J, et al.
21 ACE Inhibitors, ARBs and Other Anti-Hypertensive Drugs and Novel COVID-19:
22 An Association Study from the COVID Symptom Tracker App in 2,215,386
23 Individuals. *SSRN Electronic Journal*. 2020. [preprint]
- 24 44. Huh K, Ji W, Kang M, Hong J, Bae GH, Lee R, et al. Association of previous
25 medications with the risk of COVID-19: a nationwide claims-based study from
26 South Korea. *medRxiv*. 2020. [preprint]
- 27 45. Kolin DA, Kulm S, Elemento O. Clinical and Genetic Characteristics of Covid-
28 19 Patients from UK Biobank. *medRxiv*. 2020. [preprint]
- 29 46. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, et al.
30 Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United
31 States Veterans Aged 54-75 Years. *medRxiv*. 2020. [preprint]
- 32 47. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al.
33 Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. *N Engl J*
34 *Med*. 2020;382(25):2441-8.
- 35 48. Shah SJ, Barish PN, Prasad PA, Kistler AL, Neff N, Kamm J, et al. Clinical
36 features, diagnostics, and outcomes of patients presenting with acute respiratory
37 illness: a comparison of patients with and without COVID-19. *medRxiv*. 2020.
38 [preprint]
- 39 49. Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, et al. Role of Drugs
40 Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity
41 of COVID-19: A Large Case-Control Study from Zhejiang Province, China.
42 *medRxiv*. 2020. [preprint]
- 43 50. Michelena X, Borrell H, Lopez-Corbeto M, Lopez-Lasanta M, Moreno E,
44 Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and paediatric

- 1 patients with rheumatic diseases treated with targeted biologic and synthetic
- 2 disease-modifying anti-rheumatic drugs. *Semin Arthritis Rheum.* 2020;50(4):564-70.
- 3 51. Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, et al. ACE-
- 4 inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe
- 5 SARS- COVID19 infection in a multi-site UK acute Hospital Trust. *medRxiv.* 2020.
- 6 [preprint]
- 7 52. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al.
- 8 Characterization and clinical course of 1000 Patients with COVID-19 in New York:
- 9 retrospective case series. *medRxiv.* 2020. [preprint]
- 10 53. Cao C, Chen M, Li Y, Yu L, Huang W, Qian G, et al. Clinical Features and
- 11 Predictors for Patients with Severe SARS-CoV-2 Pneumonia: A Retrospective
- 12 Multicenter Cohort Study. *SSRN Electronic Journal.* 2020. [preprint]
- 13 54. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and
- 14 mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.*
- 15 2020;146(1):110-8.
- 16 55. Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and
- 17 progression of acute respiratory distress syndrome in coronavirus disease 2019.
- 18 *medRxiv.* 2020. [preprint]
- 19 56. Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M,
- 20 et al. Determinants of Severity in Cancer Patients with COVID-19 Illness. *medRxiv.*
- 21 2020. [preprint]
- 22 57. Wang D, Wang J, Jiang Q, Yang J, Li J, Gao C, et al. No Clear Benefit to the Use
- 23 of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A
- 24 Retrospective Cohort Study. *medRxiv.* 2020. [preprint]
- 25 58. Lui GC-Y, Yip TC-F, Wong VW-S, Chow VC-Y, Ho TH-Y, Li TC-M, et al.
- 26 Adverse Clinical Outcomes in COVID-19 Versus SARS: A Territory-Wide Cohort
- 27 Study in Hong Kong. *SSRN Electronic Journal.* 2020. [preprint]
- 28 59. Monreal E, Maza SSdl, Gullón P, Natera-Villalba E, Chico-García JL, Beltrán-
- 29 Corbellini Á, et al. Immunosuppression is associated with a lower risk of moderate
- 30 to severe acute respiratory distress syndrome in COVID-19. *Research Square.* 2020.
- 31 [preprint]
- 32 60. Zhu L, Gong N, Liu B, Lu X, Chen D, Chen S, et al. Coronavirus Disease 2019
- 33 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10
- 34 Confirmed Cases in Wuhan, China. *Eur Urol.* 2020;77(6):748-54.
- 35 61. Benelli G, Buscarini E, Canetta C, La Piana G, Merli G, Scartabellati A, et al.
- 36 SARS-COV-2 comorbidity network and outcome in hospitalized patients in Crema,
- 37 Italy. *medRxiv.* 2020. [preprint]
- 38 62. Chen M, Fan Y, Wu X, Zhang L, Guo T, Deng K, et al. Clinical Characteristics
- 39 And Risk Factors For Fatal Outcome in Patients With 2019-Coronavirus Infected
- 40 Disease (COVID-19) in Wuhan, China. *SSRN Electronic Journal.* 2020. [preprint]
- 41 63. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular
- 42 Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-
- 43 19). *JAMA Cardiol.* 2020.

64. Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, et al. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. medRxiv. 2020. [preprint]
65. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020.
66. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9.
67. Sánchez-Álvarez JE, Fontán MP, Martín CJ, Pelicano MB, Reina CJC, Prieto ÁMS, et al. Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). Nefrología (English Edition). 2020;40(3):272-8.
68. Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. medRxiv. 2020. [preprint]
69. Lee H-Y, Ahn J, Kang CK, Won S-H, Park J-H, Kang CH, et al. Association of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome. SSRN Electronic Journal. 2020. [preprint]
70. Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ res. 2020.
71. Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, et al. Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):748-55.
72. Liang M, Chen P, He M, Tang J, He X, Zhou Y, et al. Corticosteroid Treatment in Critically Ill Patients with COVID-19: A Retrospective Cohort Study. Research Square. 2020. [preprint]
73. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020.
74. Zhang S, Zhao J, Wu Z, Shang Y, Zheng J, Meng M, et al. Potential Predictors for Disease Progression and Medication Evaluation of 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. SSRN Electronic Journal. 2020. [preprint]
75. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
76. Lu X, Chen T, Wang Y, Wang J, Yan F. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Crit Care. 2020;24(1):241.

- 1 77. George MP, Masur H, Norris KA, Palmer SM, Clancy CJ, McDyer JF.
2 Infections in the immunosuppressed host. *Ann Am Thorac Soc*. 2014;11 Suppl
3 4(Suppl 4):S211-20.
- 4 78. Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME, et
5 al. Recommendations for coronavirus infection in rheumatic diseases treated with
6 biologic therapy. *J Autoimmun*. 2020;109:102442.
- 7 79. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood
8 Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2
9 Diabetes. *Cell Metab*. 2020;31(6):1068-77 e3.
- 10 80. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of
11 hypertension and antihypertensive treatment with COVID-19 mortality: a
12 retrospective observational study. *Eur Heart J*. 2020;41(22):2058-66.
- 13 81. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity
14 and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur*
15 *Respir J*. 2020;55(5):2000547.
- 16 82. Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Caulfield
17 MJ, et al. Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic
18 populations is not explained by cardiometabolic, socioeconomic or behavioural
19 factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank.
20 *Journal of Public Health*. 2020;42(3):451-60.
- 21 83. Dambha-Miller H, Albasri A, Hodgson S, Wilcox CR, Khan S, Islam N, et al.
22 Currently prescribed drugs in the UK that could upregulate or downregulate ACE2
23 in COVID-19 disease: a systematic review. *BMJ Open*. 2020;10(9):e040644.
- 24 84. Lumpuy-Castillo J, Lorenzo-Almorós A, Pello-Lázaro AM, Sánchez-Ferrer C,
25 Egidio J, Tuñón J, et al. Cardiovascular Damage in COVID-19: Therapeutic
26 Approaches Targeting the Renin-Angiotensin-Aldosterone System. *Int J Mol Sci*.
27 2020;21(18).
- 28 85. Chu C, Zeng S, Hasan AA, Hoher C-F, Krämer BK, Hoher B. Comparison of
29 infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung
30 infection under renin-angiotensin-aldosterone system blockade: Systematic review
31 and meta-analysis. *British Journal of Clinical Pharmacology*. n/a(n/a).
- 32 86. Mortensen E, Anzueto A. Prior use of both a statin and ARB is associated with
33 lower mortality for patients hospitalized with pneumonia. *European Respiratory*
34 *Journal*. 2016;48(suppl 60):OA3329.
- 35 87. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of
36 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
37 Wuhan, China. *JAMA*. 2020;323(11):1061-9.
- 38 88. Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of
39 immunomodulatory and biologic agents for severe cutaneous disease: An
40 Australia/New Zealand consensus statement. *The Australasian journal of*
41 *dermatology*. 2020;07.
- 42 89. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.
43 COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*.
44 2020;395(10229):1033-4.

- 1 90. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical
2 features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He
3 He Hu Xi Za Zhi. 2020;43(0):E005.
- 4 91. Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al.
5 Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory
6 failure: a case report. Ann Oncol. 2020;31(7):961-4.
- 7 92. Gnanenthiran SR, Borghi C, Burger D, Charchar F, Poulter NR, Schlaich MP, et
8 al. Prospective meta-analysis protocol on randomised trials of renin-angiotensin
9 system inhibitors in patients with COVID-19: an initiative of the International
10 Society of Hypertension. BMJ Open. 2021;11(2):e043625.
- 11 93. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. Early, low-dose and
12 short-term application of corticosteroid treatment in patients with severe COVID-19
13 pneumonia: single-center experience from Wuhan, China. medRxiv. 2020. [preprint]
- 14 94. Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement
15 Addresses Concerns Re: Using RAAS Antagonists in COVID-19. J Card Fail.
16 2020;26(5):370.
- 17 95. British Society for Rheumatology. COVID-19 guidance 2020 [cited 2020 Jul 29].
18 Available from: [https://www.rheumatology.org.uk/practice-quality/covid-19-](https://www.rheumatology.org.uk/practice-quality/covid-19-guidance)
19 [guidance](https://www.rheumatology.org.uk/practice-quality/covid-19-guidance).
- 20 96. Guys & St Thomas' NHS Foundation Trust. Dermatology and coronavirus:
21 frequently asked questions 2020 [cited 2020 Jul 29]. Available from:
22 [https://www.guysandstthomas.nhs.uk/our-services/dermatology/dermatology-and-](https://www.guysandstthomas.nhs.uk/our-services/dermatology/dermatology-and-coronavirus-frequently-asked-questions.aspx#na)
23 [coronavirus-frequently-asked-questions.aspx#na](https://www.guysandstthomas.nhs.uk/our-services/dermatology/dermatology-and-coronavirus-frequently-asked-questions.aspx#na).
- 24 97. National Institute for Health and Care Excellence. COVID-19 rapid evidence
25 summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for
26 people with or at risk of COVID-19 2020 [cited 2020 Jul 29]. Available from:
27 <https://www.nice.org.uk/advice/es25/chapter/Key-messages>.
- 28 98. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of
29 Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report.
30 medRxiv. 2020:2020.06.22.20137273. [preprint]
- 31 99. CTU Bern. CORON-ACT started enrollment 2020 [cited 2020 Jul 28]. Available
32 from:
33 [https://www.ctu.unibe.ch/about_us/news/coron_act_started_enrollment/index_eng.](https://www.ctu.unibe.ch/about_us/news/coron_act_started_enrollment/index_eng.html)
34 [html](https://www.ctu.unibe.ch/about_us/news/coron_act_started_enrollment/index_eng.html).
- 35 100. Beale R, Carter B, Douthwaite S, Williams S, Mehta M, Lynch E, et al. Lipid
36 Ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to
37 COVID-19: a multicentre, randomised, controlled trial (The Liberate Trial) BTD
38 Health2020 [cited 2020 Jul 28]. Available from: <https://btd-health.com/>.
- 39 101. Chen L. Atorvastatin as Adjunctive Therapy in COVID-19 (STATCO19) NIH
40 U.S. National Library of Medicine2020 [cited 2020 Jul 28]. Available from:
41 <https://clinicaltrials.gov/ct2/show/NCT04380402>.
- 42 102. Jardine M, Wilcox A. Controlled evaluation of Angiotensin Receptor Blockers
43 for COVID-19 respIraTorY Disease (CLARITY): NIH U.S. National Library of
44 Medicine; 2020 [cited 2020 Jul 28]. Available from:
45 <https://clinicaltrials.gov/ct2/show/NCT04394117>.

- 1 103. United in Research. The PACE Study: United Health Group; 2020 [cited 2020
- 2 Jul 28]. Available from: <https://www.unitedinresearch.com/studies/2>.

3

4

1 Appendix 1: search terms

2 First search (Ovid)

- 3 1. Coronavirus Infections/ or covid-19.mp. or Betacoronavirus/
- 4 2. Pneumonia, Viral/ or Severe Acute Respiratory Syndrome/ or sars-cov-2.mp.
- 5 or SARS Virus/
- 6 3. Pandemics/ or ncov-2019.mp.
- 7 4. 2019-nCov.mp. or Spike Glycoprotein, Coronavirus/
- 8 5. 1 or 2 or 3 or 4
- 9 6. Analgesics/ or Anti-Inflammatory Agents, Non-Steroidal/ or non-
- 10 steroidal.mp or Cyclooxygenase 2 Inhibitors/
- 11 7. Ibuprofen.mp. or ibuprofen/
- 12 8. Angiotensin-Converting Enzyme Inhibitor?.mp. or Angiotensin-Converting
- 13 Enzyme Inhibitors/
- 14 9. ACE Inhibitor?.mp.
- 15 10. Antihypertensive Agents/ or Angiotensin Receptor Antagonists/ or
- 16 ARB?.mp. or Angiotensin II Type 1 Receptor Blockers/
- 17 11. Angiotensin Receptor Blocker?.mp.
- 18 12. Angiotensin II Receptor Blocker?.mp.
- 19 13. Steroid?.mp. or Steroids/
- 20 14. Corticosteroid?.mp. or Adrenal Cortex Hormones/
- 21 15. Immunosuppressant?.mp. or Immunosuppressive Agents/
- 22 16. ((drug? or medication? or prescri*) adj10 (harm or safe* or risk or worse* or
- 23 sever* or discontinue? or unsafe or avoid)).mp. [mp=ti, ab, ot, nm, hw, fx, kf,
- 24 ox, px, rx, ui, an, sy, tn, dm, mf, dv, kw, dq]
- 25 17. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
- 26 18. 5 and 17
- 27 19. Limit 18 to yr="2019-Current"

28

1 **Second search (WHO COVID-19 database)**

- 2 1. NSAID*
- 3 2. Non-steroid*
- 4 3. Analgesi*
- 5 4. Ibuprofen
- 6 5. ACE Inhibitor*
- 7 6. ACE-I*
- 8 7. ACEI*
- 9 8. Angiotensin Converting Enzyme Inhibitor*
- 10 9. Renin-Angiotensin-Aldosterone System Inhibitor*
- 11 10. Renin-Angiotensin-Aldosterone System Blocker*
- 12 11. RAAS Inhibitor*
- 13 12. RAAS Blocker*
- 14 13. *pril
- 15 14. Antihypertensive*
- 16 15. Angiotensin Receptor Blocker*
- 17 16. ARB*
- 18 17. *sartan
- 19 18. *steroid*
- 20 19. *cortico*
- 21 20. Immunosuppressant*
- 22 21. Immunosuppressive*
- 23 22. Immunomodulat*
- 24 23. Immune modulat*
- 25 24. Antimineralocorticoid*
- 26 25. Aldosterone antagonist*
- 27 26. Spironolactone
- 28 27. MCRA*
- 29 28. MRA*
- 30 29. Mineralocorticoid Receptor Antagonist*

- 1 30. *statin*
- 2 31. HMG CoA Reductase Inhibitor*
- 3 32. Thiazolidinedione*
- 4 33. *glitazone*

5 **Third search (NIH iSearch COVID-19 portfolio)**

- 6 1. NSAID
- 7 2. Non-steroid
- 8 3. Analgesi*
- 9 4. Ibuprofen
- 10 5. ACE Inhibitor
- 11 6. ACE-I
- 12 7. ACEI
- 13 8. Angiotensin Converting Enzyme Inhibitor
- 14 9. "Renin-Angiotensin-Aldosterone System Inhibitor"
- 15 10. "Renin-Angiotensin-Aldosterone System Blocker"
- 16 11. "RAAS Inhibitor"
- 17 12. "RAAS Blocker"
- 18 13. *pril
- 19 14. Antihypertensive
- 20 15. Angiotensin Receptor Blocker
- 21 16. ARB
- 22 17. *sartan
- 23 18. *steroid*
- 24 19. *cortico*
- 25 20. Immunosuppressant
- 26 21. Immunosuppressive
- 27 22. Immunomodulat*
- 28 23. "Immune modulator"
- 29 24. Antimineralocorticoid

- 1 25. "Aldosterone antagonist"
- 2 26. Spironolactone
- 3 27. MCRA
- 4 28. MRA
- 5 29. "Mineralocorticoid Receptor Antagonist"
- 6 30. *statin
- 7 31. "HMG CoA Reductase Inhibitor"
- 8 32. Thiazolidinedione
- 9 33. *glitazone
- 10

1 **Appendix 2: inclusion & exclusion criteria**

2 **First set**

3 Inclusion criteria:

- 4 1. Papers looking at whether a medication or medications are potentially
- 5 unsafe if prescribed for patients with confirmed or suspected COVID-19 or
- 6 SARS-Cov-2 infection
- 7 2. Papers looking at whether a medication or medications should be
- 8 discontinued in patients who have confirmed or suspected COVID-19 or
- 9 SARS-Cov-2 infection and would otherwise take them regularly
- 10 3. Papers looking at the overall safety or benefits of prescribing or
- 11 discontinuing a medication or medications that have been identified as
- 12 potentially unsafe for patients under criteria 1 or 2
- 13 4. Paper addressing or responding to any paper already included in reference
- 14 to the safety of a medication or medications

15

16 Exclusion criteria:

- 17 1. Paper does not mention any specific medications or groups of medications
- 18 2. Paper not related to current COVID-19 outbreak
- 19 3. Published before November 2019
- 20 4. Paper not written in English
- 21 5. Only looking at unlicensed uses of medications, where no medication
- 22 involved has already been identified as posing a potential risk when
- 23 prescribed for its licensed use(s)
- 24 6. Only looking at medications being used for the treatment of COVID-19,
- 25 where no medication involved has already been identified as posing a
- 26 potential risk when prescribed for its licensed use(s)

- 1 7. No new data, hypothesis, guidance or recommendations stated related to
- 2 COVID-19 for any individual relevant medications

3 **Second set**

4 Inclusion criteria:

- 5 1. Studies looking at the outcomes of patients with COVID-19 or SARS-Cov-2
- 6 infection who were, or would normally be, taking medications that have
- 7 been identified in the preliminary search as potentially harmful if prescribed
- 8 for patients with confirmed or suspected COVID-19 or SARS-Cov-2 infection
- 9 (see list)
- 10 2. Studies looking at the outcomes of patients with COVID-19 or SARS-Cov-2
- 11 infection when given medications that have been identified in the
- 12 preliminary search as potentially harmful if prescribed for patients with
- 13 confirmed or suspected COVID-19 or SARS-Cov-2 infection

14 Exclusion criteria:

- 15 1. Paper does not mention any medications or groups of medications already
- 16 identified as potentially harmful
- 17 2. Paper not related to current COVID-19 outbreak
- 18 3. Published before November 2019
- 19 4. Paper not written in English
- 20 5. Paper has no primary data
- 21 6. Study not performed in vivo
- 22 7. It is unclear from the paper if the clinical outcomes follow the administration
- 23 of a medication or group of medications already identified as potentially
- 24 harmful
- 25 8. There is no measure against non-COVID-19 or non-drug exposed control

Appendix 3: study tables

Table 3. Summary of studies looking into the effect of drug groups on the susceptibility to COVID-19 infection.

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or Preprint	Drugs in meta-analyses
Caraballo, C	XSS	USA	RAASB	Community	Heart failure registry	26703	Combined	Symptomatic patients receiving positive test result	Protective	OR 0.68	0.49-0.94	Poor	None	PP	Yes
Dooley, H	XSS	UK	RAASB	Community	Self-reporting COVID app users	2215386	Combined	Self-reported positive PCR test	NSE	OR 0.87	0.66-1.13	Good	None	PP	Yes
Huh, K	CCS	South Korea	RAASB	All	Patients tested for COVID	65149	ACEI & ARB	Positive test for SARS-CoV-2 NOS	ACEI: NSE ARB: Harmful	ACEI: OR 1.25 ARB: OR 1.13	ACEI: 0.91-1.71 ARB: 1.01-1.26	Good	Age, sex, co-morbidities, location, healthcare usage and other drugs	PP	Yes
Khawaja, AP	CoS	UK	RAASB	All	UK Biobank	406793	ACEI & ARB	Hospitalization with positive test compared with general population	NSE	ACEI: OR 1.17 ARB: OR 1.00	ACEI: 0.90-1.52 ARB: 0.70-1.42	Fair	Age, sex, ethnicity and hypertension status	PP	Yes
Kolin, D	CoS	UK	RAASB	All	UK Biobank	502536	ACEI & ARB	Positive test compared with general population	NSE	ACEI: RR 1.32 ARB: RR 1.37	ACEI: 0.95-1.84 ARB: 0.94-1.98	Fair	Age, sex, BMI, systolic BP, race and deprivation	PP	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders/adjusted/matched for	Peer-review or Preprint	Drugs in meta-analyses
Mancia, G	CCS	Italy	RAASB	All	Patients with confirmed or suspected COVID	6272	ACEI & ARB	Diagnosed as per interim WHO guidelines	NSE	ACEI: OR 0.96 ARB: OR 0.95	ACEI: 0.87-1.07 ARB: 0.86-1.05	Good	Age, sex, location and co-morbidities	PR	Yes
Rentsch, CT	CoS	USA	RAASB	Hospital	VA Birth Cohort registry (54-75 years old)	3789	Combined	Positive test for SARS-CoV-2 NOS	NSE	OR: 0.98	0.78-1.23	Good	Age, sex, race, co-morbidities, vital signs, medications and health behaviours	PP	Yes
Reynolds, HR	CoS	USA	RAASB	All	Patients tested for COVID	12594	ACEI & ARB	At least one positive test	NSE	ACEI: OR 0.92 ARB: OR 1.00	ACEI: 0.79-1.08 ARB: 0.86-1.15	Good	Age, sex, race, BMI, smoking history, co-morbidities and treatment	PR	Yes
Shah, SJ	CoS	USA	RAASB	Hospital	Respiratory admissions tested for COVID	316	Combined	Positive test compared with negative test	NSE	OR: 1.24	0.49-3.13	Fair	None	PP	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders/adjusted/matched for	Peer-review or Preprint	Drugs in meta-analyses
Yan, H	CCS	China	RAASB	Hospital	Admissions with COVID	610	ACEI & ARB	Hospitalized compared with general population; Severe or critical compared with non-severe. Severe defined as one of: RR $\geq$ 30/min, SpO2 $\leq$ 93%, FiO2 $\leq$ 300mmHg, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	ACEI: NSE ARB: Protective	ACEI: OR 0.65 OR 0.24	ACEI: 0.26-1.57 ARB: 0.17-0.34	Fair	Age, sex and BMI	PP	Yes
Huh, K	CCS	South Korea	CS	All	Patients tested for COVID	65149		Positive test for SARS-CoV-2 NOS	Protective	OR 0.86	0.79-0.94	Good	Age, sex, co-morbidities, location, healthcare usage and other drugs	PP	Yes
Mancia, G	CCS	Italy	CS	All	Patients with confirmed or suspected COVID	6272	Inhaled steroids	Diagnosed as per interim WHO guidelines	Harmful	OR 1.52	1.37-1.68	Good	Age, sex, location and co-morbidities	PR	Yes
Shah, SJ	CoS	USA	CS	Hospital	Respiratory admissions tested for COVID	316		Positive test compared with negative test	NSE	OR 1.77	0.63-4.91	Fair	None	PP	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or Preprint	Drugs in meta-analyses
Yan, H	CCS	China	CS	Hospital	Admissions with COVID	610		Hospitalized compared with general population; Severe or critical compared with non-severe. Severe defined as one of: RR $\geq$ 30/min, SpO ₂ $\leq$ 93%, FiO ₂ $\leq$ 300mmHg, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	NSE	OR 1.20	0.49-2.94	Fair	Age, sex and BMI	PP	Yes
Gisondi, P	XSS	Italy	IS	All	Patients with psoriasis on biologic treatment or renal transplant patients	1223		Admission to hospital with COVID-19 compared with general population	NSE	OR 0.35	0.05-2.52	Poor	None	PR	Yes
Huh, K	CCS	South Korea	IS	All	Patients tested for COVID	65149	Mycophenolate and sirolimus	Positive test for SARS-CoV-2 NOS	NSE	Myco: OR 1.00 Siro: OR 1.16	Myco: 0.56-1.79 Siro: 0.15-8.87	Good	Age, sex, co-morbidities, location, healthcare usage and other drugs	PP	Yes
Mancia, G	CCS	Italy	IS	All	Patients with confirmed or suspected COVID	6272		Diagnosed as per interim WHO guidelines	Harmful	OR 1.30	1.20-1.42	Good	Age, sex, location and co-morbidities	PR	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or Preprint	Drugs in meta-analyses
Rentsch, CT	CoS	USA	IS	Hospital	VA Birth Cohort registry (54-75 years old)	3789		Positive test	NSE	OR 0.82	0.55-1.22	Good	Age, sex, race, co-morbidities, vital signs, medications and health behaviours	PP	Yes
Shah, SJ	CoS	USA	IS	Hospital	Respiratory admissions tested for COVID	316		Positive test compared with negative test	NSE	OR 1.57	0.61-4.08	Fair	None	PP	Yes
Huh, K	CCS	South Korea	NSAID	All	Patients tested for COVID	65149		Positive test for SARS-CoV-2 NOS	Protective	OR 0.90	0.84-0.96	Good	Age, sex, co-morbidities, location, healthcare usage and other drugs	PP	Yes
Kolin, D	CoS	UK	NSAID	All	UK Biobank	502536		Positive test compared with general population	NSE	RR 1.02	0.79-1.22	Fair	Age, sex, BMI, systolic BP, race and deprivation	PP	Yes
Mancia, G	CCS	Italy	NSAID	All	Patients with confirmed or suspected COVID	6272		Diagnosed as per interim WHO guidelines	NSE	OR 1.06	0.98-1.15	Good	Age, sex, location and co-morbidities	PR	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or Preprint	Drugs in meta-analyses
Rentsch, CT	CoS	USA	NSAID	Hospital	VA Birth Cohort registry (54-75 years old)	3789		Positive test	Harmful	OR 1.27	1.02-1.58	Good	Age, sex, race, co-morbidities, vital signs, medications and health behaviours	PP	Yes
Yan, H	CCS	China	NSAID	Hospital	Admissions with COVID	610	Aspirin	Hospitalized compared with general population	NSE	OR 1.25	0.66-2.39	Fair	Age, sex and BMI	PP	Yes
Caraballo, C	XSS	USA	Statin	Community	Heart failure registry	26703		Symptomatic patients receiving positive test result	NSE	OR 0.76	0.56-1.05	Poor	None	PP	Yes
Huh, K	CCS	South Korea	Statin	All	Patients tested for COVID	65149		Positive test for SARS-CoV-2 NOS	NSE	OR 0.99	0.89-1.10	Good	Age, sex, co-morbidities, location, healthcare usage and other drugs	PP	Yes
Mancia, G	CCS	Italy	Statin	All	Patients with confirmed or suspected COVID	6272		Diagnosed as per interim WHO guidelines	NSE	OR 1.02	0.94-1.10	Good	Age, sex, location and co-morbidities	PR	Yes
Yan, H	CCS	China	Statin	Hospital	Admissions with COVID	610		Hospitalized compared with general population	Harmful	OR 2.50	1.48-4.21	Fair	Age, sex and BMI	PP	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or Preprint	Drugs in meta-analyses
Huh, K	CCS	South Korea	TZD	All	Patients tested for COVID	65149		Positive test for SARS-CoV-2 NOS	NSE	OR 1.00	0.70-1.41	Good	Age, sex, co-morbidities, location, healthcare usage and other drugs	PP	Yes
Kolin, D	CoS	UK	TZD	All	UK Biobank	502536		Positive test compared with general population; Being admitted to hospital compared with those testing positive but remaining in the community	NSE	OR 0.94	0.35-2.57	Fair	Age, sex, BMI, systolic BP, race and deprivation	PP	Yes
Mancia, G	CCS	Italy	TZD	All	Patients with confirmed or suspected COVID	6272		Diagnosed as per interim WHO guidelines; Critical or fatal disease, critical defined as receiving MV	Harmful	OR 1.81	1.23-2.67	Good	Age, sex, location and co-morbidities	PR	Yes
Yan, H	CCS	China	TZD	Hospital	Admissions with COVID	610		Hospitalized compared with general population	NSE	OR 0.35	0.11-1.13	Fair	Age, sex and BMI	PP	Yes
Khawaja, AP	CoS	UK	MCRA	All	UK Biobank	406793		Hospitalization with positive test compared with general population	NSE	OR 1.54	0.62-3.85	Fair	Age, sex, ethnicity and hypertension status	PP	Narrative
Mancia, G	CCS	Italy	MCRA	All	Patients with confirmed or suspected COVID	6272		Diagnosed as per interim WHO guidelines	NSE	OR 0.90	0.75-1.07	Good	Age, sex, location and co-morbidities	PR	Narrative

CoS: Cohort Study, CCS: Case Control Study, XSS: Cross Sectional Study, CaseS: Case Series, NSE: No significant evidence, NVD: No verifiable data, HR: Hazard Ratio, OR: Odds Ratio, HD: high dose, LD: low dose, PR: Peer reviewed, PP: Preprint

Table 4. Summary of studies looking into the effect of drug groups on the severity of COVID-19 infection.

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or PP	Drugs in meta-analyses
Argenziano, MG	CoS	USA	RAA SB	Hospital	ED and hospital presentations with COVID	1000	Regular	Combined	Transfer to ICU	NSE	OR 1.11	0.81-1.53	Fair	None	PP	Yes
Bean, DM	CoS	UK	RAA SB	Hospital	Hospital admissions with COVID	1200	Regular	Combined	Death or admission to critical care unit for organ support within 21 days of symptom onset	Protective	OR 0.63	0.47-0.84	Good	Co-morbidities, age and sex	PP	Yes
Benelli, G	CoS	Italy	RAA SB	Hospital	Admissions with COVID	411	Regular	ACEIs & ARBs	Requiring NIV or CPAP	ACEI: Harmful ARB: NSE	ACEI: OR 1.95 ARB: OR 1.68	ACEI: 1.06-3.60 ARB: 0.94-2.99	Fair	None	PP	Yes
Dauchet, L	XSS	France	RAA SB	All	Patients with confirmed or suspected COVID	288	Regular	ACEIs & ARBs	ICU admission; Being put through to emergency line due to symptoms	ACEI: NSE ARB: Harmful	ACEI: SPR 0.95 ARB: SPR 1.56	ACEI: 0.55-1.64 ARB: 1.02-2.39	Good	None	PP	Yes
Feng, Y	XSS	China	RAA SB	Hospital	Admissions with COVID	476	Regular	Combined	Critical compared with moderate: critical defined as respiratory failure requiring MV, shock or requiring ICU care. Moderate defined as fever, cough and pneumonia on chest CT but RR<30/min, SpO ₂ >93% and FiO ₂ >300mmHg (i.e not severe)	Protective	OR 0.17	0.05-0.52	Fair	None	PR	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or PP	Drugs in meta-analyses
Feng, Z	CoS	China	RAA SB	Hospital	Admissions with COVID	564	Regular	Combined	Severe or critical compared with non-severe. Severe defined as one of: RR ≥ 30 /min, SpO2 $\leq 93\%$, FiO2 ≤ 300 mmHg, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	NSE	OR 0.41	0.05-3.19	Good	Propensity score matched and adjusted for age, gender, smoking history, co-morbidities and lung CT score	PP	Yes
Kolin, D	CoS	UK	RAA SB	All	UK Biobank	502536	Regular	ACEIs & ARBs	Being admitted to hospital compared with those testing positive but remaining in the community	NSE	ACEI: 0.56 ARB: 0.60	ACEI: 0.26-1.22 ARB: 0.25-1.42	Fair	Age, sex, BMI, systolic BP, race and deprivation	PP	Yes
Li, J	Case S	China	RAA SB	Hospital	Hypertensive COVID admissions	1178	Regular	Combined	Severe compared with non-severe. Severe defined as one of: RR ≥ 30 /min, SpO2 $\leq 93\%$, FiO2 ≤ 300 mmHg, lung infiltrates more than 50% within 24 to 48 hours, respiratory failure and/or multi-organ failure	NSE	OR 1.11	0.71-1.73	Good	None	PR	Yes
Li, X	CoS	China	RAA SB	Hospital	Admissions with COVID	548	Regular	Combined	Severe or critical compared with non-severe. Severe defined as per IDSA & ATS guidelines for CAP	NSE	OR 0.86	0.45-1.61	Good	Age, sex, blood tests, antiviral usage	PR	Yes
Liu, Yingxia	CoS	China	RAA SB	Hospital	Hypertensive COVID admissions	78	Regular	ACEIs & ARBs	Severe compared with non-severe as per NHCPRC 2019-nCoV guidelines	NSE	ACEI: OR 0.57 ARB: OR 0.54	ACEI: 0.11-2.95 ARB: 0.25-1.16	Fair	Sex	PP	Yes
Mancia, G	CCS	Italy	RAA SB	All	Patients with confirmed or suspected COVID	6272	Regular	ACEIs & ARBs	Critical or fatal disease, critical defined as receiving MV	NSE	ACEI: OR 0.91 ARB: OR 0.83	ACEI: 0.69-1.21 ARB: 0.63-1.10	Good	Age, sex, location and co-morbidities	PR	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or PP	Drugs in meta-analyses
Meng, J	CoS	China	RAA SB	Hospital	Hypertensive COVID admissions	42	Regular	Combined	Severe disease or death, severe defined as per NHCPRC 2019-nCoV guidelines	NSE	OR 0.28	0.07-1.12	Fair	None	PR	Yes
Rentsch, CT	CoS	USA	RAA SB	Hospital	VA Birth Cohort registry (54-75 years old)	3789	Regular	Combined	Hospitalization compared with community care after testing positive	NSE	OR 1.15	0.71-1.87	Good	Age, sex, race, co-morbidities, vital signs, medications and health behaviours	PP	Yes
Reynolds, HR	CoS	USA	RAA SB	All	Patients tested for COVID	12594	Regular	ACEIs & ARBs	ICU admission, MV or death	NSE	ACEI: OR 0.90 ARB: OR 0.99	ACEI: 0.70-1.14 ARB: 0.79-1.25	Good	Age, sex, race, BMI, smoking history, co-morbidities and treatment	PR	Yes
Yan, H	CCS	China	RAA SB	Hospital	Admissions with COVID	610	Regular	ACEIs & ARBs	Severe or critical compared with non-severe. Severe defined as one of: RR $\geq 30/\text{min}$, SpO2 $\leq 93\%$, FiO2 $\leq 300\text{mmHg}$, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	NSE	ACEI: OR 1.23 ARB: OR 0.77	ACEI: 0.19-7.93 ARB: 0.36-1.63	Fair	Age, sex and BMI	PP	Yes
Yang, G	CoS	China	RAA SB	Hospital	Hypertensive COVID admissions	126	Regular	Combined	Severe or critical compared with non-severe. Severe defined as one of: RR $\geq 30/\text{min}$, SpO2 $\leq 93\%$, FiO2 $\leq 300\text{mmHg}$, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	NSE	OR 0.73	0.34-1.58	Fair	None	PP	Yes
Zeng, Z	CoS	China	RAA SB	Hospital	Hypertensive COVID Admissions	75	Regular	Combined	Severe compared with non-severe. Severe defined as per IDSA & ATS guidelines for CAP	NSE	OR 2.46	0.94-6.45	Poor	None	PP	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or PP	Drugs in meta-analyses
Argenziano, MG	CoS	USA	CS	Hospital	ED and hospital presentations with COVID	1000	Regular	Inhaled, nasal, oral steroids	Transfer to ICU	NSE	OR 1.06	0.59-1.90	Fair	None	PP	Yes
Cao, C	CoS	China	CS	Hospital	Admissions with mild-moderate COVID	58	Acute	Methylprednisolone	Severe compared with non-severe. Severe defined as one of: RR $\geq$ 33/min, SpO ₂ $\leq$ 94% at rest, PO ₂ /FiO ₂ $\leq$ 300mmHg, requiring MV, developing shock or multiple organ failure requiring ICU	Protective	OR 0.14	0.02-0.80	Fair	None	PP	Narrative
Li, X	CoS	China	CS	Hospital	Admissions with COVID	548	Regular	Oral	Severe or critical compared with non-severe. Severe defined as per IDSA & ATS guidelines for CAP	NSE	Oral: OR 0.51 Inh: OR 0.69	Oral: 0.09-2.84 Inh: 0.11-4.16	Good	Age, sex, blood tests, antiviral usage	PR	Yes
Liu, Yanli	CoS	China	CS	Hospital	Admissions with COVID	109	Acute		Berlin definition of ARDS	NSE	OR 1.38	0.64-2.98	Fair	None	PP	Narrative
Lui, GCY	CoS	China	CS	Hospital	Admissions with COVID	114	Acute	Methylprednisolone	ICU admission, MV or death	Harmful	HR 4.17	1.23-14.11	Poor	Age, sex, co-morbidities and blood markers	PP	OR incalculable or inaccurate
Robilotti, EV	CoS	USA	CS	Hospital	Cancer patients with symptomatic COVID	423	Regular	Steroids or lymphopaenia	Requiring high-flow oxygen or MV	NSE	OR 1.52	0.92-2.50	Fair	Age, race, treatment and co-morbidities	PP	Yes
Wang, D	CoS	China	CS	Hospital	Admissions with COVID	115	Acute	Methylprednisolone	ICU admission or death	NSE	OR 2.16	0.49-9.43	Poor	Age, sex, co-morbidities and blood markers	PP	Narrative

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or PP	Drugs in meta-analyses
Yan, H	CCS	China	CS	Hospital	Admissions with COVID	610	Regular		Hospitalized compared with general population; Severe or critical compared with non-severe. Severe defined as one of: RR ≥ 30 /min, SpO ₂ $\leq 93\%$, FiO ₂ ≤ 300 mmHg, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	Harmful	OR 7.56	1.17-48.93	Fair	Age, sex and BMI	PP	Yes
Yi, P	CoS	China	CS	Hospital	Admissions with COVID	100	Acute		Severe or critical compared with non-severe. Severe defined as one of: RR ≥ 30 /min, SpO ₂ $\leq 93\%$, FiO ₂ ≤ 300 mmHg, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	NSE	-	-	Fair	Age and BMI	PP	OR incalculable or inaccurate
Li, X	CoS	China	IS	Hospital	Admissions with COVID	548	Regular		Severe or critical compared with non-severe. Severe defined as per IDSA & ATS guidelines for CAP	NSE	OR 0.35	0.11-4.16	Good	Age, sex, blood tests, antiviral usage	PR	Yes
Monreal, E	CoS	Spain	IS	Hospital	Admissions with COVID	138	Regular		Berlin definition for ARDS	Protective	OR 0.16	0.05-0.52	Fair	Age, sex and time of onset	PP	Yes
Rentsch, CT	CoS	USA	IS	Hospital	VA Birth Cohort registry (54-75 years old)	3789	Regular		Hospitalization compared with community care after testing positive	NSE	OR 1.62	0.75-3.50	Good	Age, sex, race, comorbidities, vital signs, medications and health behaviours	PP	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or PP	Drugs in meta-analyses
Robilotti, EV	CoS	USA	IS	Hospital	Cancer patients with symptomatic COVID	423	Regular	Chemotherapy	Requiring high-flow oxygen or MV	NSE	OR 1.16	0.76-1.78	Fair	Age, race, treatment and co-morbidities	PP	Yes
Roumier, M	CCS	France	IS	Hospital	Admissions with COVID	60	Acute	Tocilizumab	Requiring MV	Protective	OR 0.42	0.20-0.89	Fair	Matched for age, sex and severity	PP	No
Zhu, L	CCS	China	IS	Hospital	Renal transplant admissions with COVID	10	Regular		Severe compared with non-severe. Severe defined as per 7th edition of NHCPRC 7th version; Time from onset to shedding (unclear); Recovery compared with death	Harmful	-	-	Fair	None	PR	OR incalculable or inaccurate
Argenziano, MG	CoS	USA	NSAID	Hospital	ED and hospital presentations with COVID	1000	Regular		Transfer to ICU	NSE	OR 0.78	0.55-1.11	Fair	None	PP	Yes
Castro, VM	XSS	USA	NSAID	Community	Patients tested for COVID	2271	Regular	Ibuprofen, naproxen, ketorolac	Being admitted to hospital compared with those testing positive but remaining in the community	Protective and harmful	Ibu: OR 0.65 Nap: OR 0.39 Ket: OR 1.70	Ibu: 0.42-0.99 Nap: 0.14-0.93 Ket: 1.03-2.78	Good	Age, sex, race, Charlston index, location	PP	Yes
Hong, W	CoS	China	NSAID	Hospital	Admissions with COVID	44	Acute	Celecoxib	Progression to severe or critical disease. Severe defined as one of: RR ≥ 30 /min, SpO2 $\leq 93\%$, FiO2 ≤ 300 mmHg. Critical defined as one of: requiring MV, shock, requiring ICU care for organ support	NSE	-	-	Poor	None	PP	No

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or PP	Drugs in meta-analyses
Kolin, D	CoS	UK	NSAID	All	UK Biobank	502536	Regular		Being admitted to hospital compared with those testing positive but remaining in the community	NSE	RR 0.75	0.47-1.18	Fair	Age, sex, BMI, systolic BP, race and deprivation	PP	Yes
Kragholm, K	CCS	Denmark	NSAID	All	National registry (>30 years old without heart failure)	1872	Regular	Ibuprofen	Severe disease, ICU admission or death. Severe disease defined as ICD-10 code for severe adult respiratory syndrome	NSE	OR 1.57	0.72-3.38	Fair	Age, sex and co-morbidities	PP	Yes
Rentsch, CT	CoS	USA	NSAID	Hospital	VA Birth Cohort registry (54-75 years old)	3789	Regular		Hospitalization compared with community care after testing positive	Harmful	OR 1.18	0.74-1.89	Good	Age, sex, race, co-morbidities, vital signs, medications and health behaviours	PP	Yes
Yan, H	CCS	China	NSAID	Hospital	Admissions with COVID	610	Regular	Aspirin	Severe or critical compared with non-severe. Severe defined as one of: RR ≥ 30 /min, SpO2 $\leq 93\%$, FiO2 ≤ 300 mmHg, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	Protective and harmful	OR 0.51	0.12-2.13	Fair	Age, sex and BMI	PP	Yes
Argenziano, MG	CoS	USA	Statin	Hospital	ED and hospital presentations with COVID	1000	Regular		Transfer to ICU	NSE	OR 1.20	0.89-1.63	Fair	None	PP	Narrative
Yan, H	CCS	China	Statin	Hospital	Admissions with COVID	610	Regular		Severe or critical compared with non-severe. Severe defined as one of: RR ≥ 30 /min, SpO2 $\leq 93\%$, FiO2 ≤ 300 mmHg, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	Harmful	OR 0.98	0.32-2.99	Fair	Age, sex and BMI	PP	Narrative

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Specific drugs	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/matched for	Peer-review or PP	Drugs in meta-analyses
Yan, H	CCS	China	TZD	Hospital	Admissions with COVID	610	Regular		Severe or critical compared with non-severe. Severe defined as one of: RR ≥ 30 /min, SpO2 $\leq 93\%$, FiO2 ≤ 300 mmHg, critical defined as one of: requiring MV, shock, requiring ICU care for organ support	NSE	OR 4.52	0.34-59.54	Fair	Age, sex and BMI	PP	Yes

CoS: Cohort Study, CCS: Case Control Study, XSS: Cross Sectional Study, CaseS: Case Series, NSE: No significant evidence, NVD: No verifiable data, HR: Hazard Ratio, OR: Odds Ratio, HD: high dose, LD: low dose, PR: Peer reviewed, PP: Preprint

Table 5. Summary of studies looking into the effect of drug groups on the mortality from COVID-19 infection

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/ matched for	Peer-review or Preprint	Drugs in meta-analyses
Benelli, G	CoS	Italy	RAA SB	Hospital	Admissions with COVID	411	Regular	Deaths compared with discharges and inpatients	NSE	ACEI: OR 1.39 ARB: OR 1.54	ACEI: 0.67-2.86 ARB: 0.79-2.98	Fair	None	PP	Yes
Chen, Ming	CCS	China	RAA SB	Hospital	Deaths and discharges from hospital with COVID	123	Regular	Deaths compared with discharges	NSE	OR 1.13	0.28-4.54	Fair	None	PP	Yes
Guo, T	XSS	China	RAA SB	Hospital	Admissions with COVID	187	Regular	Deaths compared with discharges	NSE	OR 1.70	0.63-4.58	Fair	None	PR	Yes
Ip, A	CCS	USA	RAA SB	Hospital	Hypertensive COVID discharges and deaths	1216	Regular	Deaths compared with discharges	Protective	OR 0.66	0.51-0.85	Poor	None	PP	Yes
Lee, HY	CoS	South Korea	RAA SB	All	Patients with lab confirmed COVID	8266	Regular	Mortality within 60 days	NSE	HR 1.07	0.68-1.65	Good	Age, sex and co-morbidities	PP	Narrative
Li, J	CaseS	China	RAA SB	Hospital	Hypertensive COVID admissions	1178	Regular	In hospital death compared with discharges	NSE	OR 0.76	0.44-1.33	Good	None	PR	Yes
Richardson, S	CaseS	USA	RAA SB	Hospital	Hypertensive COVID discharges and deaths	5700	Regular	In hospital death compared with discharges	NSE	ACEI: OR 1.34 ARB: OR 1.21	ACEI: 0.94-1.91 ARB: 0.89-1.65	Fair	None	PR	Yes
Sánchez - Álvarez, JE	XSS	Spain	RAA SB	All	Renal replacement patients with COVID	375	Regular	In hospital death compared with cured cases	Protective	OR 0.59	0.39-0.90	Poor	None	PR	Yes

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/ matched for	Peer-review or Preprint	Drugs in meta-analyses
Yang, G	CoS	China	RAA SB	Hospital	Hypertensive COVID admissions	126	Regular	Deaths compared with discharges and inpatients	NSE	OR 0.32	0.07-1.51	Fair	None	PP	Yes
Zhang, P	CoS	China	RAA SB	Hospital	Hypertensive COVID admissions	1128	Regular	28 day mortality	Protective	HR 0.37	0.15-0.89	Good	Matched for age, sex, symptoms, co-morbidities, CT findings, CRP and creatinine. Adjusted for location, treatment, D-Dimer and unilateral lesion	PR	Narrative
Cao, J	CoS	China	CS	Hospital	Admissions with COVID	102	Acute	All deaths occurring in data collection period compared with those discharged	NSE	OR 2.06	0.70-6.09	Fair	None	PR	Yes
Chen, Ming	CCS	China	CS	Hospital	Deaths and discharges from hospital with COVID	123	Acute	Deaths compared with discharges	Harmful	OR 4.75	1.78-12.66	Fair	None	PP	Yes
Li, X	CoS	China	CS	Hospital	Admissions with COVID	548	Acute	Deaths at any point from admission until final date of follow up (4 weeks after last admission)	HD: Harmful LD: NSE	HD: HR 3.5 LD: HR 1.26	HD: 1.79-6.86 LD: 0.61-2.58	Good	Age, sex, blood tests, antiviral usage	PR	Narrative
Liang, M	CoS/ CCS	China	CS	Hospital	Admissions with COVID	120	Acute	Death during hospital stay	NSE	OR 0.65	0.10-4.14	Good	None	PP	Yes
Liu, Yanli	CoS	China	CS	Hospital	Admissions with COVID	109	Acute	Deaths compared with discharges	NSE	-	-	Fair	None	PP	OR incalculable or inaccurate
Lu, X	CoS	China	CS	ICU	Critical COVID discharges and deaths	244	Acute	28 day mortality	NSE	-	-	Good	Propensity score matched and adjusted for age, SpO2 and lymphocyte count	PP	OR incalculable or inaccurate

First Author	Design	Country	Drug Group	Setting	Population	Sample Size	Acute or Regular	Outcome definitions	Result	Statistic	95% CI	Quality	Confounders adjusted/ matched for	Peer-review or Preprint	Drugs in meta-analyses
Sánchez - Álvarez, JE	XSS	Spain	CS	All	Renal replacement patients with COVID	375	Acute	In hospital death compared with cured cases	Harmful	OR 1.81	1.12-2.91	Poor	None	PR	Yes
Wu, C	CoS	China	CS	Hospital	COVID patients with ARDS	201	Acute	Death at any point up to 18 days after recruitment	Protective	HR 0.38	0.20-0.72	Fair	None	PR	Yes
Zhang, S	CoS	China	CS	Hospital	Admissions with COVID	262	Acute	28 day mortality	Harmful	OR 4.97	2.85-8.45	Poor	None	PP	Yes
Zhou, F	CoS	China	CS	Hospital	Admissions with COVID	191	Acute	Deaths compared with discharges	Harmful	OR 3.18	1.63-6.19	Poor	None	PR	Yes
Monreal, E	CoS	Spain	IS	Hospital	Admissions with COVID	138	Regular	Deaths compared with those with a final outcome	NSE			Fair	Age, sex and time of onset	PP	Yes
Roumier, M	CCS	France	IS	Hospital	Admissions with COVID	60	Acute	In-hospital deaths within 2 days of end of recruitment period	NSE			Fair	Matched for age, sex and severity	PP	No

CoS: Cohort Study, CCS: Case Control Study, XSS: Cross Sectional Study, CaseS: Case Series, NSE: No significant evidence, NVD: No verifiable data, HR: Hazard Ratio, OR: Odds Ratio, HD: high dose, LD: low dose, PR: Peer reviewed, PP: Preprint

Appendix 4: funnel plots

Fig 12. Funnel plot to assess for publication bias from studies measuring susceptibility to COVID-19 in those taking RAASBs. *ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio.*

Fig 13. Funnel plot to assess for publication bias from studies measuring severity of COVID-19 in those taking RAASBs. *ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio.*

Appendix 5: data collection table headings

Result (#)
Study (#)
First Author
Journal
Type (Peer reviewed or preprint)
Date
Country
Setting (Hospital, community or both)
Sample Size
Drug Group
Specific Drug(s)
Regular or Acute
Study Design
Population Demographic
Cited by (#)
Outcome (1-6)
Significance (harm, benefit or no statistically significant evidence)
Odds Ratio/Relative Risk
p-value
Confidence Intervals
Control Group
Subgroup(s) Affected
Identified Confounding Factors
Comments

Appendix 6: forest plots

Fig 14. Forest plot for effect of NSAIDs on severity of COVID-19. NSAID – non-steroidal anti-inflammatory drug, OR – odds ratio, CI – confidence interval.

Fig 15. Forest plot for effect of NSAIDs on susceptibility to COVID-19. NSAID – non-steroidal anti-inflammatory drug, OR – odds ratio, CI – confidence interval.

Fig 16. Forest plot for effect of statins on susceptibility to COVID-19. OR – odds ratio, CI – confidence interval.

Fig 17 . Forest plot for effect of TZDs on susceptibility to COVID-19. TZD - thiazolidinediones, OR – odds ratio, CI – confidence interval.

Fig 18. Forest plot of susceptibility to COVID-19 for those taking regular RAAS blockers, split by drug group. ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio, CI – confidence interval.

Fig 19. Forest plot of susceptibility to COVID-19 for those taking regular RAAS blockers, split by study design. ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio, CI – confidence interval.

Fig 20. Forest plot of susceptibility to COVID-19 for those taking regular RAAS blockers, split by level of adjustment. ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin-II-receptor blocker, OR – odds ratio, CI – confidence interval.

Appendix 7: sensitivity analysis for removal of preprints

Peer-Reviewed Before Study	Subsequently Peer-Reviewed	Not Peer-Reviewed
Cao, J	Argenziano, MG	Benelli, G
Feng, Y	Bean, DM	Cao, C
Gisondi, P	Caraballo, C	Castro, VM
Guo, T	Hong, W	Chen, M
Li, J	Huh, K	Dauchet, L
Li, X	Kolin, DA	Dooley, H
Mancia, G	Kragholm, K	Feng, Z
Meng, J	Lu, X	Ip, A
Reynolds, HR	Michelen, X	Khawaja, AP
Richardson, S	Monreal, E	Lee, HY
Sánchez-Álvarez, JE	Robilotti, EV	Liang, M
Wu, C	Shah, SJ	Liu, Yingxia
Zhang, P	Wang, D	Liu, Yanli
Zhou, F	Yang, G	Lui, GCY
Zhu, L	Yi, P	Rentsch, CT
		Roumier, M
		Yan, H
		Zeng, Z
		Zhang, S

RAAS blockers

Corticosteroids

No meta-analysis was performed for susceptibility with corticosteroids.

Severity with acute corticosteroids leaves Wang, D only: OR 2.16 (95% CI 0.49 – 9.43).

Immunosuppressants

Susceptibility with immunosuppressants had one study not peer reviewed (Rentsch CT et al.) and sensitivity analysis was run for this already within the study.

No meta-analysis was performed for mortality related to immunosuppressants.

NSAIDs, statins, TZDs

No meta-analyses were performed for mortality related to either NSAIDs, statins or TZDs.

No meta-analyses were performed for severity related to either statins or TZDs.

No meta-analyses were performed for MCRA.